NUS Medicine Researchers Identify Doxycycline as Potential Treatment for Central Nervous System Tuberculosis

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have identified doxycycline, a commonly used antibiotic, as a potential treatment for Central Nervous System Tuberculosis (CNS-TB). CNS-TB is a severe form of tuberculosis that impacts the brain and spinal cord, often leading to life-threatening complications. The preclinical study conducted by the research team indicates that doxycycline may offer therapeutic benefits in addressing this condition.

The study highlights that doxycycline, which is both widely available and cost-effective, demonstrated promising results in combating CNS-TB during laboratory testing. Researchers focused on repurposing the antibiotic due to its established safety profile and accessibility. The findings suggest that doxycycline could play a role in reducing inflammation and improving outcomes for patients suffering from CNS-TB. Further investigation will be required to confirm its efficacy in clinical settings and determine optimal treatment protocols.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 12, 2025

Related posts:

Generic Drug Prices Affected by API Costs, Manufacturing, and FDA Regulations Trump Administration Targets Prescription Drug Costs with Multifaceted Strategy, Outcome Uncertain Northwestern Medicine Researchers Refine High-Resolution Manometry Analysis for Esophageal Motor Disorder Diagnosis Study Explores Telemedicine’s Role in Addiction Care for Recently Released Incarcerated Individuals

Author

GOAI